Sebastiano Calandra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sebastiano Calandra has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Patrizia Tarugi
Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
4 shared publications - Maurizio Averna
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy
3 shared publications - Angelo Baldassare Cefalu'
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy
2 shared publications - Laura D'ERasmo
Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy
2 shared publications - Livia Pisciotta
Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy
2 shared publications - Manuela Casula
Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan , Milan 20133
2 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (12) , 2264-2276
Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry
BACKGROUND: We aimed to compare the molecular and clinical characteristics of patients identified in Italy as affected by either familial chylomicronemia syndrome (FCS) or multifactorial chylomicronemia syndrome (MCS) and to assess the overall benefit of novel triglyceride-lowering therapies prescribed to these patients within the routine clinical care. METHODS: From the national LIPIGEN-sHTG (Lipid Transport Disorders Italian Genetic Network—Severe Hypertriglyceridemia) registry, 169 patients (57 FCS, 51 MCS, 61 variant-negative, variant-negative MCS) were retrospectively analyzed. Data on clinical and genetic characteristics, medical history, and medications were collected. Peak triglyceride levels were used to define untreated lipid phenotypes. RESULTS: In FCS, 72% exhibited biallelic LPL and 28% non-LPL variants; in MCS, 38% (n=19) carried LPL variants, and 38% (n=19) carried APOA5 variants, whereas the remaining individuals were carriers of LMF1 (n=3), GPIHBP1 (n=2), and CREB3L3 or GPD1 variants (n=8), respectively. Peak TGs were highest in FCS (3000 mg/dL [interquartile range, 2116.0–4265.0]), followed by MCS (1817 mg/dL [interquartile range, 1370.0–3062.0]) and variant-negative MCS (1340.0 mg/dL [interquartile range, 946.5–2508.5]; P LPL variants. Lomitapide and volanesorsen provide better triglyceride control, yet only one-third of FCS were treated with these drugs in the routine clinical practice.
- 1 December 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (12) , 2264-2276
Open AccessContemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry
BACKGROUND: We aimed to compare the molecular and clinical characteristics of patients identified in Italy as affected by either familial chylomicronemia syndrome (FCS) or multifactorial chylomicronemia syndrome (MCS) and to assess the overall benefit of novel triglyceride-lowering therapies prescribed to these patients within the routine clinical care. METHODS: From the national LIPIGEN-sHTG (Lipid Transport Disorders Italian Genetic Network—Severe Hypertriglyceridemia) registry, 169 patients (57 FCS, 51 MCS, 61 variant-negative, variant-negative MCS) were retrospectively analyzed. Data on clinical and genetic characteristics, medical history, and medications were collected. Peak triglyceride levels were used to define untreated lipid phenotypes. RESULTS: In FCS, 72% exhibited biallelic LPL and 28% non-LPL variants; in MCS, 38% (n=19) carried LPL variants, and 38% (n=19) carried APOA5 variants, whereas the remaining individuals were carriers of LMF1 (n=3), GPIHBP1 (n=2), and CREB3L3 or GPD1 variants (n=8), respectively. Peak TGs were highest in FCS (3000 mg/dL [interquartile range, 2116.0–4265.0]), followed by MCS (1817 mg/dL [interquartile range, 1370.0–3062.0]) and variant-negative MCS (1340.0 mg/dL [interquartile range, 946.5–2508.5]; P LPL variants. Lomitapide and volanesorsen provide better triglyceride control, yet only one-third of FCS were treated with these drugs in the routine clinical practice.
- 7 May 2024
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (8) , 1819-1836
Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)
- 7 May 2024
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (8) , 1819-1836
Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)
- 1 April 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1861 (4) , 371-379
Characterization of a mutant form of human apolipoprotein B (Thr26_Tyr27del) associated with familial hypobetalipoproteinemia
- 1 April 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1861 (4) , 371-379
Characterization of a mutant form of human apolipoprotein B (Thr26_Tyr27del) associated with familial hypobetalipoproteinemia
- 1 October 2012
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 22 (10) , 831-835
Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia
- 1 October 2012
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 22 (10) , 831-835
Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia
- 9 February 2009
- Published by Wiley in Journal of Internal Medicine
- Vol. 265 (3) , 359-372
Severe HDL deficiency due to novel defects in the ABCA1 transporter
: Objectives. The objective was the identification and functional characterization of mutations in the ABCA1 gene in four patients with severe HDL deficiency.Subjects. Patients were referred to the clinic because of almost complete HDL deficiency.Methods. The ABCA1 gene was sequenced directly. The analysis of the ABCA1 protein, ABCA1 mRNA and ABCA1‐mediated cholesterol efflux was performed in cultured fibroblasts. Intracellular localization of ABCA1 mutants was investigated in transfected HEK293 cells.Results. Two patients were homozygous for mutations in the coding region of the ABCA1 gene, resulting in an amino acid substitution (p.A1046D) and a truncated protein (p.I74YFsX76). The third patient was homozygous for a splice site mutation in intron 35 (c.4773 + 1g>a), resulting in an in‐frame deletion of 25 amino acids (del p.D1567_K1591) in ABCA1. These patients had clinical manifestations of accumulation of cholesterol in the reticulo‐endothelial system. The fourth patient, with preclinical atherosclerosis, was a compound heterozygote for two missense mutations (p.R587W/p.W1699C). ABCA1‐mediated cholesterol efflux was abolished in fibroblasts from patients with p.A1046D and del p.D1567_K1591 mutants and in fibroblasts homozygous for p.R587W. A reduced ABCA1 protein content was observed in these cells, suggesting an increased intracellular degradation. The mutant p.W1699C was largely retained in the endoplasmic reticulum, when expressed in HEK293 cells.Conclusions. The homozygotes for mutations which abolish ABCA1 function showed overt signs of involvement of the reticulo‐endothelial system. This was not the case in the compound heterozygote for missense mutations, suggesting that this patient retains some residual ABCA1 function that reduces cholesterol accumulation in the reticulo‐endothelial system.
- 9 February 2009
- Published by Wiley in Journal of Internal Medicine
- Vol. 265 (3) , 359-372
Severe HDL deficiency due to novel defects in the ABCA1 transporter
: Objectives. The objective was the identification and functional characterization of mutations in the ABCA1 gene in four patients with severe HDL deficiency.Subjects. Patients were referred to the clinic because of almost complete HDL deficiency.Methods. The ABCA1 gene was sequenced directly. The analysis of the ABCA1 protein, ABCA1 mRNA and ABCA1‐mediated cholesterol efflux was performed in cultured fibroblasts. Intracellular localization of ABCA1 mutants was investigated in transfected HEK293 cells.Results. Two patients were homozygous for mutations in the coding region of the ABCA1 gene, resulting in an amino acid substitution (p.A1046D) and a truncated protein (p.I74YFsX76). The third patient was homozygous for a splice site mutation in intron 35 (c.4773 + 1g>a), resulting in an in‐frame deletion of 25 amino acids (del p.D1567_K1591) in ABCA1. These patients had clinical manifestations of accumulation of cholesterol in the reticulo‐endothelial system. The fourth patient, with preclinical atherosclerosis, was a compound heterozygote for two missense mutations (p.R587W/p.W1699C). ABCA1‐mediated cholesterol efflux was abolished in fibroblasts from patients with p.A1046D and del p.D1567_K1591 mutants and in fibroblasts homozygous for p.R587W. A reduced ABCA1 protein content was observed in these cells, suggesting an increased intracellular degradation. The mutant p.W1699C was largely retained in the endoplasmic reticulum, when expressed in HEK293 cells.Conclusions. The homozygotes for mutations which abolish ABCA1 function showed overt signs of involvement of the reticulo‐endothelial system. This was not the case in the compound heterozygote for missense mutations, suggesting that this patient retains some residual ABCA1 function that reduces cholesterol accumulation in the reticulo‐endothelial system.
- 1 October 1993
- Published by Springer Nature in Human Genetics
- Vol. 92 (4) , 424-426
Chorionic DNA analysis for the prenatal diagnosis of familial hypercholesterolaemia
Prenatal diagnosis for familial hypercholesterolaemia (FH) was performed by using restriction fragment length polymorphisms (RFLPs) of the LDL receptor gene on chorionic villi DNA taken during the 10th week of pregnancy. Both parents were FH heterozygotes and had previously had a healthy son and an FH homozygous son. Two RFLPs were informative in this family and revealed that the fetus was unaffected by FH. At birth the child was found to have an LDL cholesterol level of 30 mg/dl and a normal LDL receptor activity in cultured umbilical cord fibroblasts. RFLP analysis on chorionic villi DNA is highly recommended for all heterozygous FH couples in whom the LDL receptor gene mutation/s is/are still to be characterized.
- 1 October 1993
- Published by Springer Nature in Human Genetics
- Vol. 92 (4) , 424-426
Chorionic DNA analysis for the prenatal diagnosis of familial hypercholesterolaemia
Prenatal diagnosis for familial hypercholesterolaemia (FH) was performed by using restriction fragment length polymorphisms (RFLPs) of the LDL receptor gene on chorionic villi DNA taken during the 10th week of pregnancy. Both parents were FH heterozygotes and had previously had a healthy son and an FH homozygous son. Two RFLPs were informative in this family and revealed that the fetus was unaffected by FH. At birth the child was found to have an LDL cholesterol level of 30 mg/dl and a normal LDL receptor activity in cultured umbilical cord fibroblasts. RFLP analysis on chorionic villi DNA is highly recommended for all heterozygous FH couples in whom the LDL receptor gene mutation/s is/are still to be characterized.
- Open Access
- 1 March 1990
- Published by Elsevier in Journal of Lipid Research
- Vol. 31 (3) , 417-427
Absence of apolipoprotein B-48 in the chick, Gallus domesticus.
- 1 March 1990
- Published by Elsevier in Journal of Lipid Research
- Vol. 31 (3) , 417-427
Open AccessAbsence of apolipoprotein B-48 in the chick, Gallus domesticus.